Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Who the F*** would sell when we are just waiting ond the fast track response and should have it within 60days
Ended up with way more buys than sells just didn't move us out of the red for whatever reason
Someone must know something
Has phase 1 of the clinical trials started yet???
Whats next? When should we expect news next?
If there are not enough funds hopefully they are not running the price up just to make an offering.
Not enough funds to finish trials? What about the grants? Oh well someone will buy them out !!!!
Hopefully you’re right
Huge Buy out !
If what I am thinking is right .. we could see $20 very soon !
Looks like them $9's got chewed up 10mins after close..
Must be big news coming
NICE BUMP TODAY !!!!
What's going on????????
I was thinking we would have made some money today... Guess not
Nathan, it’s an IND. Pre-IND was done long time ago. That said it’s a tedious process to compile all of the documents and requires a lot of QC review. As noted in PR, we rely on many 3rd parties to get it all together.
4:35 PM · Mar 19, 2021 from Los Angeles, CA·Twitter for iPhone
Come on brady get your thrid party people moving so us longs can finally make some money!!! I though it was supposta be done in February? Covid didnt slow it down either you say..
Got a response from brady via Twitter
Still being put together. See PR last month and report from Zacks earlier this month. I’m as eager as anyone Nathan
6:01 PM · Feb 22, 2021 from Norwalk, CA·Twitter for iPhone
I though the app was supposed to be completed the beginning of this month? Brady letting us down again?
I wish! Have long ways to get back to even
We should be popping anytime ladys and gentlemen
It's been a long time since I checked on this. Is that a good a bad thing?
Grant should be up 1-31-21 so we should be getting close to knowing whats up.. Id hope..
Can't say I disagree with you at this point.
Pretty sure all this company does anymore is issue their own directors shares. If yinz remember that’s exactly what I said was going to happen with the RS. People argued with me on here saying, “Brady’s shares will be shortened as well”. Ya but they just issue themselves more shares. Oh well... hope they eventually get through clinical on into them. Be honest I don’t even know where they are at at this point.
Yes very true, but it all goes back to who’s going to pay ??, still need insurance to step up!
There will be tons of opioid addicts and alcoholics after this Covid mess!
Brady -
You’re not getting up-listed. Reverse your reverse split and give those of us who’ve lost $20K+ in value a chance to recoup. This was a good stock when it was in penny land, and clearly the company has no business getting up listed for a few more years, at best...
Do they have any idea when they will bring the compound to market? It seems like they are only surviving because of the grants that bicx has received.
I agree. Looks like Brady answered your question directly with today's update.
Would do a whole lot better if this company could get anything done. Any ideas if and when any clinical trials will begin?
How's everyone doing?
The initial post was about the grant money...nothing else. All the other info you included to indicate "bad news" was already known.
Money is good , what is BAD is that after leading investors to think they were ready to market the implant years ago.
Now they are telling us they haven't even started human trials yet.
Meaning they are years away from a saleable product.
That is not good news at all.
No significant clinical advancement of product no significant raise in share price.
Now how is that good.
My bad...you're right, it's bad news to receive the second half of the grant...
Not really.
Our goal this year is to get IND approval so that we can start conducting human studies.”
Just trying to understand your position and math? If they raised $$ below $15 then how many shares were issued? What substantial amount of royalties have been paid?
huh?
what part of my post that you are responding to in which I specifically stated that BICX raised $6 million was wrong, as you claim?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152886298
WRONG! BICX raised $6M.
WRONG! BICX raised $6M.
Thanks for the heads- up here...GL
Scam company BICX continues with its FALSE AND MISLEADING statements. This time on the $15.00/share pricing of the $6.0 million private placement. The price was significantly below $15.00/share since a substantial Royalty Agreement also came with the common shares for the $6.0 million
not surprised though
and why is this not surprising?
because this is what scam companies do!
News - BioCorRx Provides 2019 Year-End Business Update
Press Release | 12/19/2019
ANAHEIM, CA, Dec. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a year-end business update for 2019 and reported on recent corporate developments.
Brady Granier, CEO, President, and Director of BioCorRx, Inc., stated, “2019 was a transformative year for our Company as we achieved a number of major milestones. In the beginning of the year, we were awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), for the development of BICX102, a sustained release naltrexone implant for the treatment of opioid and alcohol use disorders. This grant is expected to substantially cover our financial costs towards FDA approval and further validates the clinical potential of BICX102 for the treatment of opioid and alcohol use disorders.
“We continue to advance BICX102 through the regulatory pathway. Over the summer, we entered into a Master Services Agreement with Charles River Laboratories, Inc., to begin conducting preclinical studies of BICX102, which are still underway. We have also partnered with IRISYS to manufacture and develop BICX102. IRISYS brings extensive and valuable experience beyond manufacturing that should also contribute to our success as we move forward through the clinical and regulatory process for BICX102. Our goal for 2020 is to get IND approval so that we can start conducting human studies.
“We recently provided an update on VDM-001, a new opioid antagonist being developed to reverse opioid overdose through our partnership with VDM Biochemicals, Inc. (VDM). VDM-001 may represent an effective alternative to naloxone in the overdose reversal market. Early preclinical data showed that the effects of fentanyl, which is responsible for thousands of deaths annually, may be prevented by VDM-001. One potential benefit of VDM-001 may be a shorter and less costly manufacturing cycle as it is purely synthetic. We look forward to working with VDM in order to further explore this molecule.
“This year we launched our UnCraveRx™ program, which is a medically assisted weight loss management program that includes on-demand, virtual lifestyle support, fitness and nutrition via mobile app designed to be used in conjunction with anti-craving medication if determined medically appropriate by a patient’s treating physician and under their medical supervision. The program is designed to help providers’ client success by helping them stay on track with their weight loss goals. As we work towards expanding our provider network, we believe that the program will be a key growth revenue driver for BioCorRx.”
Lourdes Felix, CFO, COO and Director, stated, “In order to prepare us for the planned up-listing to the Nasdaq Capital Markets, we recently converted the note with Alpine Creek Partners, which eliminates $4.16 million of liabilities from our balance sheet. This significantly enhances our capital structure and dramatically improves our balance sheet. Notably, in the second quarter of this year, we raised $6 million in a private placement at $15 per share, which was significantly above market. We continue to receive strong support from our current investors as well as Alpine Creek, a strategic partner since 2016. For this reason, we decided to withdraw the S-1 registration statement. Our goal is to minimize dilution as we advance BICX102 through the regulatory pathway and we believe withdrawing the S-1 registration statement is in the best interest of our shareholders. We would like to wish everyone happy and healthy holidays and we look forward to providing further updates in the new year.”
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. The BioCorRx® Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance use; please visit www.beataddiction.com for more information on the BioCorRx Recovery Program. The UnCraveRx™ Weight Loss Program is also a medication assisted program; please visit www.uncraverx.com for more information on UnCraveRx™. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, please visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
Followers
|
134
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
12599
|
Created
|
10/10/10
|
Type
|
Free
|
Moderators |
![]() |
About BioCorRxProgram OverviewBioCorRx (OTCBB: BICX) is an alcohol treatment and rehabilitation company on the leading edge of alcohol addiction treatment. The company has developed a treatment program that is used by various licensed alcohol addiction clinics throughout the United States. The program consists of two components:BioCorRx has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of the FDA-approved drug, naltrexone. After being surgically implanted by a medical professional, the naltrexone implant significantly reduces cravings for alcohol for as long as a year in some patients, depending on individual metabolism rates.BioCorRx also owns a life coaching program that is tailored specifically to alcoholics. Once a patient has received the implant, they are encouraged to enter the life coaching program to maximize results. BioCorRx’s revolutionary alcohol treatment program has an 85% success rate as reported by patients in routine telephone and face to face interviews. The implant is administered as an outpatient procedure, and in most cases, patients do not need to miss more than one day of work. They are then able to enter the private life coaching program without co-workers or family members knowing, unless they so choose. |
TechnologyNaltrexone is a medication that blocks the effects of drugs known as opioids and was approved by the FDA in 1995 for the treatment of alcohol dependence. Learn more about the side effects of naltrexone. Naltrexone blocks the parts of the brain that "feel pleasure” when patients use alcohol. When these areas of the brain are blocked, patients feel significantly less cravings for alcohol and even if alcohol is used, the effects of it will be extremely limited - making sobriety the only option. Once medical intervention has reduced the physical need for alcohol, the program goes on to address the patient's psychological needs. The combination of these treatments has resulted in the highest chance of sobriety. ![]() While other companies use naltrexone in their treatments, the drug is typically administered in oral or injection form, requiring their patients to be responsible for taking the medication or scheduling an appointment. While some patients do well with the oral formulation, there is a drawback that it must be taken daily and a patient whose craving becomes overwhelming can obtain the euphoria simply by skipping a dose before resuming abuse. Patients who received the program developed by BioCorRx are treated with a slow release dose that can last up to year in many patients (depending on various factors such as metabolism rates), which gives the patients a higher success rate for the treatment of alcoholism. The outpatient naltrexone implant procedure can take as little as 20 minutes under local anesthetic in some cases. Most patients can return to work or their daily routine in the same day, without the cravings for alcohol. |
![]() |
Mission, Vision, ValuesMissionBioCorRx is focused on providing leadership and innovation for the treatment of alcoholism by offering a high-quality, comprehensive and cost-effective recovery program that allows patients and their loved ones to celebrate freedom from the cycle of alcohol addiction. Our program is built on a strong foundation of experience and practice, allowing for an improved quality of life for recovering alcoholics. VisionBioCorRx strives to be the preeminent, long-term alcohol recovery program used by treatment centers around the world for alcoholics, as well as their family and friends. By providing patients a "Fresh Start" on life, they have the opportunity to live happier, healthier, more productive lives away from the damaging impact of alcohol. We have built an organization that is committed to nurturing research for cutting-edge alcohol recovery technologies and integrating those technologies with comprehensive alcohol recovery treatment programs. ValuesBioCorRx provides the opportunity and tools to treatment centers so they can help patients live happier, healthier, and more productive lives to those suffering from alcohol addiction (as well as their family and friends) by helping them break the addiction cycle and live alcohol-free. We want patients to celebrate freedom from the past and hope for the future. Our team consists of physicians, coaches, founders and management that are committed to providing high-quality services and adherence to ethical care. Our goal is to give our treatment center partners the ability to deliver our program in a timely, warm and compassionate way to give patients, as well as their families and friends, peace of mind. To achieve this, BioCorRx has built its program around highly-qualified alcohol addiction specialists and effective treatment solutions. We are committed to quality and continuous improvement in order to meet our partners’ needs for an individualized program dedicated to alcohol addiction recovery. |
![]() |
Investors OverviewBioCorRx is uniquely poised to gain significant market share of the $22 billion annual alcohol treatment market in the US. More than 7% of the US population ages 18 years and older or 13.8 million Americans have problems with drinking, including 8.1 million people who suffer from alcoholism. And the costs financially are staggering. Alcohol dependency and abuse costs the US over $220 billion a year. For the sake of comparison, this is greater than the amount of money spent to combat cancer ($196 billion) and obesity ($133 billion). BioCorRx intends to distribute the program to a new clinic in the United States every 60 to 90 days. Clinics using our program are also holding discussions with major health insurance providers to pay for all or a portion of the treatment fees. Business ModelBioCorRx’s research has discovered that demand for its services are high and that growth in highly marketed segments of the population may be achieved through partnering with additional clinic sites. The company is also exploring the sub-licensing of the program to select regions of the US and internationally. BioCorRx's goal is to meet its growth targets through licensing opportunities by promoting its naltrexone implant product and counseling service model to existing medical clinics and treatment centers that will purchase the program and/or product from the company. In addition, Fresh Start Private intends to open corporately owned clinics in select key markets where it is deemed appropriate. Stock Price & ChartsBioCorRx is a fully reporting company. Financial reports and other reports are available for view or by visiting the OTCBB.com online website. Audited financial reports are available quarterly. Company Structure Details
|
BICX Chart
Key Executives
• Kent Emry - CEO, Director
• Brady Granier -COO, Director
• Lourdes Felix -CFO, Director
• Dr. Jorge Andrade, Jr. - Director
• Neil Muller -Co-Founder and President, Director
Locations
Locations of independently owned clinics using our Fresh Start Program
Start Fresh Recovery
720 N. Tustin Ave.
Suite 206
Santa Ana, CA 92705
714-541-6100
800-916-1099
www.startfreshrecovery.com
www.stopdrinkingUSA.com
Start Fresh Executive Recovery
367 E Virginia Ave
Phoenix, AZ 85004
855-393-HOPE (4673)
www.ExecutiveRecovery.net
Fresh Start Private Florida
1415 Panther Lane
Suites 313-320
Naples, FL 34109
800-985-7574
www.FreshStartPrivateFlorida.com
Start Fresh Alcohol Recovery Center
2827 S. 88th St
Omaha NE 68124
402-884-1221
www.startfreshNE.com
Coming Soon!
Insider Interview Links
December 2, 2013 - thewallstreetanalyzer.com Interview with Brady Granier COO
November 14, 2013 - SmallCapVoice Interview with Kent Emry CEO
October 2, 2013 - SmallCapVoice Interview with Brady Granier COO